Revista Mexicana de Oftalmología

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  97 (2023)
Volume  96 (2022)
Volume  95 (2021)
Volume  94 (2020)
Volume  93 (2019)
Volume  92 (2018)
Related articles

VOLUME 95 , ISSUE 5E ( September-October, 2021 ) > List of Articles

REVIEW ARTICLE

SARS-CoV-2: is it present in the conjunctiva?

Héctor J. Pérez-Cano, Óscar Morales-López, Monserrat Y. Garrido-Santos, Selma A. Somilleda-Ventura

Keywords : Conjunctiva, Coronavirus, Tear, Pandemic, SARS-CoV-2

Citation Information : Pérez-Cano HJ, Morales-López Ó, Garrido-Santos MY, Somilleda-Ventura SA. SARS-CoV-2: is it present in the conjunctiva?. 2021; 95 (5E):203-207.

DOI: 10.24875/RMOE.M21000182

License: CC BY-NC-ND 4.0

Published Online: 01-09-2021

Copyright Statement:  Copyright © 2021 Sociedad Mexicana de Oftalmología. Published by Permanyer


Abstract

The Orthocoronavirinae family was discovered in the 1960s. These are enveloped viruses with positive single-stranded RNA, and their genome size varies approximately between 26 and 32 kb, being the largest genome for an RNA virus. In Mexico, the first reported case was that of a person from Italy. Taking this first case as day 1, the cases have been increasing and, at the time of writing this article, there were 133,974 infected people and 15,944 deaths. The conjunctiva has been proposed as a route of entry for SARS-CoV-2. However, in a search for coronavirus genetic material in tear and conjunctiva samples, patients who did not show conjunctivitis were negative for the presence of viral genetic material, and only one person was positive, both in tear and conjunctiva samples. Negative results for SARS-CoV-2 RNA in tears and conjunctival secretions could indicate that the virus does not replicate in conjunctival epithelia, but could be present in undetectable amounts, which does not rule out that it can be transmitted through the conjunctiva.

PDF Share
  1. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17:181-92.
  2. Hu B, Ge X, Wang LF, Shi Z. Bat origin of human coronaviruses. Virol J. 2015;12:221.
  3. Siddell SG, Anderson R, Cavanagh D, Fujiwara K, Klenk HD, Macnaughton MR, et al. Coronaviridae. Intervirology. 1983;20:181-9.
  4. de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016; 14:523-34.
  5. Gorbalenya AE, Snijder EJ, Spaan WJM. Severe acute respiratory syndrome coronavirus phylogeny: toward consensus. J Virol. 2004;78:7863-6.
  6. Oxford JS, Bossuyt S, Lambkin R. A new infectious disease challenge: Urbani severe acute respiratory syndrome (SARS) associated coronavirus. Immunology. 2003;109:326-8.
  7. Mackay IM, Arden KE. MERS coronavirus: diagnostics, epidemiology and transmission. Virol J. 2015;12:222.
  8. Mo P, Xing Y, Xiao Y, Deng L, Zhao Q, Wang H, et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin Infect Dis. 2020. Mar 16:ciaa270. doi: 10.1093/cid/ciaa270. Online ahead of print.
  9. Peng Y, Zhou YH. Is novel coronavirus disease (COVID-19) transmitted through conjunctiva? J Med Virol. 2020;92:1408-9.
  10. Jin X, Lian JS, Hu JH, Gao J, Zheng L, Zhang YM, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut. 2020; 69:1002-9.
  11. Kannan S, Shaik Syed Ali P, Sheeza A, Hemalatha K. COVID-19 (novel coronavirus 2019) — recent trends. Eur Rev Med Pharmacol Sci. 2020;24:2006-11.
  12. Madabhavi I, Sarkar M, Kadakol N. COVID-19: a review. Monaldi Arch Chest Dis. 2020;90(2).
  13. Devaux CA, Rolain JM, Raoult D. ACE2 receptor polymorphism: susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome. J Microbiol Immunol Infect. 2020;53:425-35.
  14. Atluri S, Manchikanti L, Hirsch JA. Expanded umbilical cord mesenchymal stem cells (UC-MSCs) as a therapeutic strategy in managing critically ill COVID-19 patients: the case for compassionate use. Pain Physician. 2020;23:E71-83.
  15. Cheng ZJ, Shan J. 2019 Novel coronavirus: where we are and what we know. Infection. 2020;48:155-63.
  16. Peng X, Xu X, Li Y, Cheng L, Zhou X, Ren B. Transmission routes of 2019-nCoV and controls in dental practice. Int J Oral Sci. 2020;12:9.
  17. Ge ZY, Yang LM, Xia JJ, Fu XH, Zhang YZ. Possible aerosol transmission of COVID-19 and special precautions in dentistry. J Zhejiang Univ Sci B. 2020;21:361-8.
  18. Setti L, Passarini F, De Gennaro G, Barbieri P, Perrone MG, Borelli M, et al. Airborne transmission route of COVID-19: why 2 meters/6 feet of inter-personal distance could not be enough. Int J Environ Res Public Health. 2020;17:2932.
  19. Chen Y, Chen L, Deng Q, Zhang G, Wu K, Ni L, et al. The presence of SARS-CoV-2 RNA in the feces of COVID-19 patients. J Med Virol. 2020;92:833-40.
  20. Hernández G. SARS: epidemiología y mecanismos de transmisión. Med Intensiva 2003;27:686-91.
  21. Cano F, Gajardo M, Freundlich M. Eje renina angiotensina, enzima convertidora de angiotensina 2 y coronavirus. Rev Chil Pediatr. 2020;91:330-8.
  22. Soler MJ, Lloveras J, Batlle D. Enzima conversiva de la angiotensina 2 y su papel emergente en la regulación del sistema renina-angiotensina. Med Clin (Barc). 2008;131:230-6.
  23. Zhou L, Xu Z, Castiglione GM, Soiberman US, Eberhart CG, Duh EJ. ACE2 and TMPRSS2 are expressed on the human ocular surface, suggesting susceptibility to SARS-CoV-2 infection. Ocul Surf. 2020;18:537-44.
  24. Collin J, Queen R, Zerti D, Dorgau B, Georgiou M, Djidrovski I, et al. Co-expression of SARS-CoV-2 entry genes in the superficial adult human conjunctival, limbal and corneal epithelium suggests an additional route of entry via the ocular surface. Ocul Surf. 2021;19:190-200.
  25. Chan WM, Yuen KS, Fan DS, Lam DS, Chan PK, Sung JJ. Tears and conjunctival scrapings for coronavirus in patients with SARS. Br J Ophthalmol. 2004;88:968-9.
  26. Seah I, Agrawal R. Can the coronavirus disease 2019 (COVID-19) affect the eyes? A review of coronaviruses and ocular implications in humans and animals. Ocul Immunol Inflamm. 2020;16:1-5.
  27. Wu P, Duan F, Luo C, Liu Q, Qu X, Liang L, et al. Characteristics of ocular findings of patients with coronavirus disease 2019 (COVID-19) in Hubei Province, China. JAMA Ophthalmol. 2020;138:575-8.
  28. Coroneo MT. The eye as the discrete but defensible portal of coronavirus infection. Ocul Surf. 2021;19:176-82.
  29. Xia J, Tong J, Liu M, Shen Y, Guo D. Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection. J Med Virol. 2020;92:589-94.
  30. Vabret A, Mourez T, Dina J, van der Hoek L, Gouarin S, Petitjean J, et al. Human coronavirus NL63, France. Emerg Infect Dis. 2005;11:1225-9.
  31. Durán CSC, Mayorga GDC. The eye: “An organ that must not be forgotten in coronavirus disease 2019 (COVID-2019) pandemic”. J Optom. 2020;14:114-9.
  32. Deng W, Bao L, Gao H, Xiang Z, Qu Y, Song Z, et al. Rhesus macaques can be effectively infected with SARS-CoV-2 via ocular conjunctival route. bioRxiv. 2020. Disponible en: https://www.biorxiv.org/content/10.1101/2020.03.13.990036v1.
  33. Li JO, Lam DSC, Chen Y, Ting DSW. Novel coronavirus disease 2019 (COVID-19): the importance of recognising possible early ocular manifestation and using protective eyewear. Br J Ophthalmol. 2020;104:297-8.
  34. Scohy A, Anantharajah A, Bodéus M, Kabamba-Mukadi B, Verroken A, Rodriguez-Villalobos H. Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis. J Clin Virol. 2020;129:104455.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.